

1. Kusari J, Tiwari R, Kumar R, and Sen G. Expression of interferon-induced genes in RD-114 cells. *J. Virol.*61, 1524-1531, 1987.
2. Kumar R, Tiwari R, Kusari J, and Sen G. Clonal derivatives of RD-114 cells respond differently in their antiviral and gene inducing responses to interferons. *J. Virol.*61, 2727-2732, 1987.
3. Kumar R, Choubey D, Lengyel P, and Sen G. Studies on the role of the 2'-5'-oligoadenylate synthetase-ribonuclease L pathway in interferon mediated inhibition of encephalomyocarditis virus replication. *J. Virol.*62, 3175-3181, 1988.
4. Kumar R, Chattopadhyay D, Banerjee AK, and Sen GA. Ribonuclease activity is associated with subviral particles isolated from interferon-treated vesicular stomatitis virus infected cells. *J. Virol.*62, 641-643, 1988.
5. Tiwari R, Kusari J, Kumar R, and Sen G. Gene induction by interferon and double-stranded RNA: selective inhibition by 2-aminopurine. *Mol. Cell. Biol.* 8, 4289-4293, 1988.
6. Kumar R, and Mendelsohn J. Studies on the role of the 2'-5'-oligoadenylate synthetase in gamma-interferon-mediated growth inhibition of A431 cells. *Cancer Res.* 49, 5180-5184, 1989.
7. Kumar R, and Sen G. Studies on interferon-mediated inhibition of retrovirus infection: use of a defective retrovirus carrying a drug resistance gene. *Virus Res.* 3, 295-302, 1989.
8. Kumar R, and Mendelsohn J. Growth regulation of A431 cells: modulation of expression of transforming growth factor-mRNA and 2'-5'-oligoadenylate synthetase activity. *J. Biol. Chem.*265, 4578-4582, 1990.
9. Ghose SK, Kusari J, Bandyopadhyay SK, Samanta H, Kumar R, and Sen GC. Cloning sequencing, and expression of two murine 2'-5'-oligoadenylate synthetases. *J. Biol. Chem.*266, 15293-15299, 1991.
10. Kumar R\*, Shepard HM, and Mendelsohn J. Regulation of phosphorylation of c-erbB2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. *Mol. Cell. Biol.* 11, 979-986, 1991 (\*Corresponding author; first report to show the inhibitory effect of Herceptin on Her2 phosphorylation).
11. Naz RK and Kumar R. Transforming growth factor 1 enhances expression of 50 kDa protein related to 2'-5'-oligoadenylate synthetase in human sperm cells. *J. Cell. Physiol.*146, 156-163, 1991.
12. Naz RK, Ahmed K, and Kumar R. Role of membrane phosphotyrosine proteins in human spermatozoal function. *J. Cell Sci.*99, 157-165, 1991.
13. \*Van de Vijver MV, \*Kumar R, and Mendelsohn J. Ligand-induced activation of A431 cell EGF receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. *J. Biol. Chem.* 266, 7503-7508, 1991. (\*equal contribution)
14. Kumar R and Atlas I. Interferon-alpha induces the expression of retinoblastoma gene product in Daudi cells. *Natl. Acad. Sci. USA.*89, 6599-6603, 1992.

15. Atlas I, Mendelsohn J, Baselga J, Masui H, Fair WR, and Kumar R. Growth regulation of human renal carcinoma cells: role of transforming growth factor-alpha. *Cancer Res.*52, 3335 - 3339, 1992.
16. Bandyopadhyay SK, Kumar R, Rubin B, and Sen GC. Interferon-inducible gene expression in HL-60 cells: effects of the state of differentiation. *Cell Growth Differ.*3, 369-375, 1992.
17. Fan Z, Mendelsohn J, Masui H, and Kumar R. Regulation of EGF receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies. *J. Biol. Chem.* 268, 21073-21079, 1993.
18. Korutla L and Kumar R. Inhibitory effect of curcumin on epidermal growth factor receptor intrinsic kinase activity in A431 cells. *Biochem. Biophys. Acta*1224, 597-600, 1994.
19. Kumar R, Korutla L, and Zhang K. Cell cycle-dependent modulation of alpha interferon inducible genes expression and activation of signaling components in Daudi cells. *J. Biol. Chem.*269, 25437-25441, 1994.
20. Kumar R and Mendelsohn J. Reduced expression of c-erbB-2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha. *Anticancer Res.*14, 1001-1008, 1994.
21. Zhang K and Kumar R. Interferon-alpha cyclin E- and cyclin D1-dependent CDK-2 kinase activity associated with RB protein and E2F in Daudi cells. *Biochem. Biophys. Res. Commun.*200, 522-528, 1994.
22. Korutla L, Cheung JY, Mendelsohn J, and Kumar R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. *Carcinogenesis*16, 1741-1745, 1995.
23. Witters LM, Curley EM, Kumar R, Chinchilli V, Harvey JP, Crebbin V, Harvey HA, and Lipton A. Detection of the epidermal growth factor receptor in the urine of patients with squamous cell carcinoma. *Clin. Cancer Res.* 1, 551-557, 1995.
24. Kumar R and Korutla R. Growth regulation of human acute promyelocytic leukemia cells by interferons and all-transretinoic acid: trans-modulation of inducible gene expression pathways. *Anticancer Res.*15, 353-360, 1995.
25. Kumar R. Dual modulation of phosphorylation of a 60 kDa nuclear protein in interferon-treated Daudi cells. *Biochem. Biophys. Res. Commun.*208, 819-824, 1995.
26. Kumar R and Korutla L. Induction of expression of interferon stimulated gene factor-3 (ISGF-3) proteins by interferons. *Exp. Cell Res.* 216, 143-148, 1995.
27. Mandal M, Maggirwar SB, Sharma N, Kaufmann SH, Sun SC, and Kumar R. Bcl-2 prevents CD-95 (Fas/APO-1)-induced degradation of lamin B and poly(ADP-ribose) polymerase, and restores the NF-kappa B signaling pathway. *J. Biol. Chem.* 271, 30354-30359, 1996.
28. Mandal M and Kumar R. Overexpression of Bcl-2 inhibits sodium butyrate-induced apoptosis in human colorectal carcinoma cells. *Carcinogenesis*18, 229-232, 1996.

29. Zhu X, Kumar R, Mandal M, Sharma N, Sharma HW, Dhingra U, Hsiao R, and Narayanan R. Cell-cycle regulation of telomerase activity in human tumor cells. *Proc Natl Acad Sci. USA* 93, 6091-6095, 1996.
30. Korutla L and Kumar R. Mechanism of interferon action: in-vivo activation of 91 kDa transcription factor by interferons. *Anticancer Res.* 16, 2789-2796, 1996.
31. Kumar R, Mandal M, Lipton A, Harvey H, and Thompson CB. Overexpression of HER2 modulates Bcl-2, Bcl-X<sub>L</sub> and Tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. *Clin. Can Res.* 2, 1215-1219, 1996.
32. Kumar R, Mandal M, Ratzkin BJ, Liu N, and Lipton A. NDF induces expression of a novel 46 kD protein in estrogen receptor positive breast cancer cells. *J. Cell Biochem.* 62, 102-112, 1996.
33. Witters LM, Kumar R, Chinchilli V, and Lipton A. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER2/neu antibody. *Breast Cancer Res. Treat.* 42, 1-5, 1996.
34. Korutla L and Kumar R. Inhibition of replication of vesicular stomatitis virus by epidermal growth factor. *Biochem. Biophys. Res. Commun.* 220, 670-674, 1996.
35. Kopreski MS, Lipton A, Harvey HA, and Kumar R. Growth inhibition of human mammary carcinoma cell lines by combinations of anti-p185/HER2 mAb and interferons, and tumor necrosis factor-alpha. *Anticancer Res.* 16, 433-436, 1996.
36. Mandal M and Kumar R. Bcl-2 expression regulates butyrate-induced apoptosis in human breast cancer MCF-7 cells. *Cell Growth Differ.* 7, 311-318, 1996.
37. Mandal M and Kumar R. Bcl-2 modulates telomerase activity. *J Biol. Chem.* 272, 14183-14187, 1997.
38. Mandal M, Wu X, and Kumar R. Bcl-2 deregulation leads to inhibition of sodium butyrate-induced apoptosis in human colorectal carcinoma cells. *Carcinogenesis* 18, 229-232, 1997.
39. Engelhardt M, Kumar R, Albanell J, Pettengell R, Han W, and Moore MAS. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. *Blood* 90, 182-193, 1997.
40. Olson DJ, Gibo DM, Sagers G, Debinski W, and Kumar R. Reversion of uroepithelial cell tumorigenesis by the ectopic expression of human wnt-5a. *Cell Growth & Differentiation* 8, 417-423, 1997.
41. Mandal M, Adam L, Mendelsohn J, and Kumar R. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. *Oncogene* 18, 999-1007, 1998.
42. Drew L, Kumar R, Bandyopadhyay D, and Gupta S. Inhibition of the protein kinase C pathway potentiates anti-CD95-induced apoptosis in Jurket T cells. *International Immunology* 10, 877-889, 1998.

43. Olson DJ, Oshimura M, Otte AP, and Kumar R. Ectopic expression of Wnt-5a in human renal cell carcinoma cells suppresses in vitro growth and telomerase activity. *Tumor Biol.* 19, 244-252, 1998.
44. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, and Kumar R. Physical interaction between EGF receptor and DNA-protein kinase in mammalian cells. *J Biol. Chem.* 273, 1568-1573, 1998.
45. Mandal M, Bandyopadhyay D, Goepfert TM, and Kumar R. Interferon induces expression of CDK inhibitors p21 and p27 that prevent activation of CDK by CAK. *Oncogene* 16, 217-225, 1998.
46. Jeng MH, Shupnik MA, Bender TP, Bandyopadhyay D, Kumar R, Masamura S, and Santen RJ. Estrogen receptor expression and function in long term estrogen deprived human breast cancer cells. *Endocrinology* 139, 4164-4174, 1998.
47. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J and Kumar, R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. *J. Biol. Chem.* 273, 28238-28246, 1998.
48. Witters L, Kumar R, Mandal M, Bennett CF, Miraglia L, and Lipton A. Antisense oligonucleotides to the epidermal growth factor receptor. *Breast Cancer Res. and Treatment* 53, 41-50, 1999.
49. Mandal M, Adam L, and Kumar R. Redistribution of activated caspase-3 to the nucleus. *Biochem. Biophys. Res. Comm.* 260, 775-780, 1999.
50. Adam L, Bandyopadhyay D and Kumar R. Interferon-Signaling Promotes Nucleus-to-cytoplasmic redistribution of p95Vav, and formation of a multisubunit complex involving Vav, Ku80 and Tyk2. *Biochem. Biophys. Res. Comm.* 267, 692-696, 1999.
51. Vadlamudi R, Mandal M, Adam L, Bandyopadhyay D, Steinbach G, Mendelsohn J, and Kumar R. Regulation of cyclooxygenase-2 by HER2 pathway. *Oncogene* 18, 305-314, 1999.
52. Vadlamudi R, Adam L, Tseng B, Costa L, and Kumar R. Transcriptional regulation of paxillin expression by heregulin in human breast cancer cells. *Cancer Res.* 59, 2843-2846, 1999.
53. Cuevas B, Lu Y, Watt S, Kumar R, Zhang J, Siminovitch KA, and Mills GB. SHP1 regulates Lck-induced PI-3 kinase phosphorylation and activity. *J. Biol. Chem.* 274, 27583-27589, 1999.
54. Vadlamudi R, Adam L, Talukder A, Mendelsohn J, and Kumar R. Serine modification of paxillin by heregulin: role of p38 mitogen-activated protein kinase. *Oncogene* 18, 7253-7264, 1999.
55. Talukder AH, Adam LA, \*Kumar R., and Avraham, R. Heregulin regulation of autocrine motility factor expression in human breast cancer cells. *Cancer Res.* 60, 474-480, 2000. (\*corresponding author)

56. Shim, Conaway, Masamura, S, Yue W, Wang S, Kumar R, and Santen RJ. Estradiol hypersensitivity and MAP kinase expression in long-term estrogen deprived human breast cancer cells in vivo. *Endocrinology* 141, 396-405, 2000.
57. Talukder AH, Vadlamudi R, Mandal M, and Kumar R. Heregulin induces expression, DNA binding activity, and transactivating functions of bZIP activating transcription factor-4. *Cancer Res.* 60, 276-281, 2000
58. Adam L, Vadlamudi R, Mandal M, Chernoff J, and Kumar R. Regulation of Microfilament Reorganization and Invasiveness of Breast Cancer Cells by p21-activated Kinase-1 K299R. *J. Biol. Chem.*275, 12041-12050, 2000.
59. Le XF, Vadlamudi R, McWatters A, Bae DS, Mills GB, Kumar R, and Bast RC. Differential signaling by an anti-p185/HER2 antibody and heregulin. *Cancer Res.* 60, 3522-3531, 2000.
60. Vadlamudi R, Adam L, Mandal M, Sahin A, Chernoff J, Hung MH, and Kumar R. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. *J. Biol. Chem.* 275, 36238-36244, 2000.
61. Yarmond R, Vadlamudi RK, Wang RA, Mendelsohn J, and Kumar R. P21-activated kinase-1 signaling mediates the expression of vascular endothelial growth factor. *J. Biol. Chem.*275, 39451-39457, 2000.
62. Vadlamudi R, Wang R, Talukder AH, Adam L, Johnson R, and Kumar R. Evidence of rab3A expression, regulation of vesicle trafficking, and cellular secretion in response to heregulin in mammary epithelial cells. *Mol. Cell. Biol.*20, 9092-9101, 2000.
63. Mandal M, Olson D, Sharma T, Vadlamudi R, and Kumar R. Butyric acid upregulates bax expression via stimulation of c-Jun N-terminal kinase/activation protein-1 pathway in human colon cancer cells. *Gastroenterology*120, 71-78, 2001.
64. Adam A, Mazumdar A, Sharma T, Jones TR, and Kumar R. Development of a Three-dimensional and Temporo-spatial Model to Study Invasiveness of Human Colorectal Cancer Cells by Heregulin and Prostaglandin E2. *Cancer Res.* 61, 81-87, 2001.
65. Mazumdar A, Adam L, Boyd D, and Kumar R. Heregulin Regulation of Urokinase Plasminogen Activator and its Receptor: Human Breast Epithelial Cell Invasion. *Cancer Res.* 61, 400-405, 2001.
66. Talukder AH, Mandal M, Vadlamudi RV, Mendelsohn J, and Kumar R. Regulation of elongation factor-1-alpha expression by growth factors and anti-receptor blocking antibodies. *J. Biol. Chem.*276, 5636-5642, 2001.
67. Mazumdar A, Wang RW, Mishra SK, Adam L, Yarmand RB, Mandal M, Vadlamudi R, and Kumar R. Transcriptional Repression of Estrogen Receptor by Metastasis-Associated Protein 1. *Nature Cell Biology* 3, 30-37, 2001.

68. Mandal M, Vadlamudi R, Nguyen D, Wang R, Costa L, Bagheri-Yarmand R, Mendelsohn J, and Kumar R. Growth factors regulation of heterogeneous nuclear ribonucleoprotein expression and functions. *J. Biol. Chem.*276, 9699-9704, 2001.
69. Adam L, Vadlamudi RK, McCrea P, and Kumar R. Tiam1 Overexpression potentiates heregulin-induced LEF/-Catenin nuclear signaling in breast cancer cells by modulating the intercellular stability. *J. Biol. Chem.*276, 28443-28450, 2001.
70. Yarmand R, Mandal M, Taludkar A, Wang R, Vadlamudi R, Kung SJ, and Kumar R. Etk/Bmx tyrosine kinase activates PAK-1 and regulates the tumorigenicity of breast cancer cells. *J. Biol. Chem.* 276, 29403-29409, 2001.
71. Vadlamudi R, Wang RW, Mazumdar A, Kim YS, Shin J, Sahin A, and Kumar R. PELP1, a novel human protein that acts as a bifunctional regulator of steroid receptors. *J. Biol. Chem.* 276, 38272-38279, 2001.
72. Li F, Mandal M, Barnes CJ, Vadlamudi RK, and Kumar R. Growth factor regulation of the molecular chaperone calnexin. *Biochem. Biophys. Res. Commun.*289, 725-732, 2001.
73. Mishra SK, Mandal M, Mazumdar A, and Kumar R. Evidence of a close linkage between chromatin remodeling status and HER2 overexpression in human breast cancer. *FEBS Lett* 507, 88-94, 2001.
74. Vadlamudi RV, Adam L, Wang RW, Nygen D, Santos M, and Kumar R. Differential regulation of components of the focal adhesion complex by heregulin: role of phosphatase SHP2. *J. Cell Physiology*, 190, 189-199, 2002.
75. Song RXD, McPherson RA, Adam L, Bao Y, Kumar R, and Santen RJ. Linkage of estrogen action to MAP kinase activation through ER alpha association with Shc signaling pathway. *Mol. Endocrinology* 16, 116-127, 2002.
76. Barnes CJ, Li F, Mandal M, Yang Z, Sahin A, and Kumar R. Heregulin Induces Expression, ATPase Activity and Nuclear Localization of G3BP, a Ras Signaling Component, in Human Breast Tumors. *Cancer Res.* 62, 1251-1255, 2002.
77. Talukder, A.H., Wang, R., and Kumar, R. Expression and transactivating functions of the bZIP transcription factor GADD153 in mammary epithelial cells. *Oncogene*21, 4289-4300, 2002.
78. Talukder, A.H., Bagheri-Yarmand, R., Williams, R.R.E., Ragoussis, J., Kumar, R., and Raz, A. Anti-HER2 antibody Herceptin inhibits autocrine motility factor expression and potentiates anti-tumor effects of AMF inhibitors. *Clinical Cancer Res.* 8, 3285-3289, 2002.
79. Mandal, M., Li, F., and Kumar, R. Heregulin upregulates heat shock protein-70 expression in breast cancer cells. *Anticancer Res.* 22, 1965-1969, 2002.
80. Vadlamudi, R.K., Feng, L., Adam, L., Nguyen, D., Ohta, Y., Stossel, T.H., and Kumar, R. Filamin is essential for p21-activated kinase 1-mediated actin cytoskeletal assembly. *Nature Cell Biology* 4, 681-690, 2002

81. Wang, RA, Mazumdar, A., Vadlamudi, R.K., and Kumar, R. P21-activated kinase phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. *EMBO J. 21*, 5437-5447, 2002
82. Kumar, R., Wang, R-W, Mazumdar, A., Talukder, A.H., Mandal, M., Yang, Z., Bagheri-Yarmand, R., Sahin, A., Hortobagyi, G., Adam, L., Barnes, C.J., and Vadlamudi, R.K., A Naturally Occurring MTA1 Variant Sequesters Estrogen Receptor in the Cytoplasm, *Nature 418*: 654-657, 2002
83. Li, F., Mandal, M., Mishra, S., Barnes, C.J., and Kumar, R. Heregulin Promotes Expression and Subcellular Redistribution of ADP-ribosylation Factor 3. *FEBS Lett. 524*, 49-53, 2002.
84. Li, F., Adam, L., Vadlamudi, R.K., Zhou, H., Sen, S., Chernoff, J., Mandal, M., and Kumar, R. P21-activated kinase 1 interacts with and phosphorylates Histone H3 in breast cancer cells. *EMBO Reports 3*, 767-773, 2002
85. Cheema, S.K., Mishra, S.K., Rangnekar, V.M., Kumar, R., Lopez-Berstein, G. PAR4 transcriptionally regulate Bcl-2 through a WT1 binding site on the Bcl-2 promoter. *J. Biol. Chem. 278*, 19995-20005, 2003.
86. Yang, Z., Bagheri-Yarmand, R., Balasenthil, S., Barnes, C.J., Hortobagyi, G., Sahin, A., and Kumar, R. HER2 Regulation of PPAR-gamma expression and sensitivity of breast cancer cells to PPAR-gamma ligand therapy. *Clin. Cancer Research 9*, 3198-3203, 2003.
87. Kouvaraki, M.A., Rassidakis, G.Z., Tian, L., Kumar, R., Kittas, C., and Claret, F.X. JAB1 Expression in breast cancer inversely correlates with the cell-cycle inhibitor p27. *Cancer Research 63*, 2977-2981, 2003.
88. Talukder, A.. H., Mishra, S.K., Mandal, M., Balasenthil, S., Mehta, S., Sahin, A..A., Barnes, C.J., and Kumar, R. MTA1 interacts with MAT1, a CAK complex ring finger factor, and regulates estrogen receptor transactivation functions. *J. Biol. Chem. 278*, 11676-11685, 2003.
89. Mazumdar, A., and Kumar, R. Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. *FEBS Lett, 535*, 6-10, 2003
90. Barnes, C.J., Yarmand-Bagheri, R., Mandal, M., Yang, Z., Clayman, G.L., Hong, W.K., and Kumar, R. Suppression of EGFR, MAPK and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa) *Mol. Cancer Therapeutics, 2*, 345-351, 2003.
91. Mishra, S.K., Mazumdar, A, Vadlamudi, R.K., Li, F., Wang, RW, Yu, W., Jordan, V.C., Santen, R.J., and Kumar, R. MICOA, a novel MTA 1 interacting protein Coactivator, regulates estrogen receptor-alpha transactivation functions. *J. Biol. Chem. 278*, 19209-19219, 2003.
92. Wang, R-W, Vadlamudi, R.K., Bagheri-Yarmand, R., Beuvink, I., Hynes, N.E., and Kumar, R. Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. *J. Cell Biology 161*, 583-592, 2003

93. Vadlamudi, R.K., Sahin, A.A., Adam, L., Wang, E., and Kumar, R. Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. *FEBS Letters* 543, 76-80, 2003.
94. Barnes, C.J., Vadlamudi, R.K., Mishra, S.K., Jacobson, R.H., Li, F., and Kumar, R. Functional inactivation of a transcriptional corepressor by a signaling kinase. *Nature Structural Biology* 10, 662-628, 2003.
95. Yang, Z., Bagheri-Yarmand, R., Wang, R., Adam, L., Papadimitrakopoulou, V.V., Clayman, G.L., El-Naggar, A., Lotan, R., Barnes, C.J., Hong, W.K., and Kumar, R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ('Iressa') suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. *Clinical Cancer Research*, 10, 658-667, 2004.
96. Balasenthil, S., Sahin, A.A, Barnes, C. J., Wang, R., Pestell, R.G., Vadlamudi, R.K, and Kumar, R. P21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. *J. Biol. Chem.* 279, 1422-1428, 2004.
97. Song, R. X-D., Barnes, C.J., Zhang, Z., Bao, Y., Kumar, R., and Senten, R.J. A novel role of Shc and IGF-1R in mediating the translocation of ER to the region of the plasma membrane in human breast cancer cells. *Proce. Natl. Acad. Sci. USA.* 101, 2076-2081, 2004.
98. Vadlamudi, R.K., Li, F., Barnes, C.J., Bagheri-Yarmand, R., and Kumar, R. p41 subunit of human Arp2/3 complex is a p21-activated kinase 1 interacting substrate. *EMBO Reports* 5, 154-160, 2004.
99. Mishra, S.K., Yang, Z., Mazumdar, A., Talukder, A.H., Larose, L. and Kumar, R. Metastatic tumor antigen 1 short form (MTA1s) associates with casein Kinase I-gamma2, an estrogen-responsive kinase. *Oncogene*, 23, 4422-4429, 2004
100. Yang, Z., Barnes, C.J., and Kumar, R. HER2 status modulates subcellular localization of and interaction with estrogen receptor-alpha in breast cancer cells. *Clinical Cancer Research*, 10, 3621-3628, 2004
101. Vadlamudi, R.K., Badheri-Yarmand, R., Yang, Z., Balasenthil, S., Nygen, D., Sahin, A.A, den Hollander, P. and Kumar, R. Dynein light chain 1, a p21-activated kinase 1 Interacting substrate, promotes cancerous phenotypes. *Cancer Cell*, 5, 575-585, 2004
102. Talukder, A., Gururaj, A., Mishra, S.K., Vadlamudi, R.K., and Kumar, R. Metastasis associated protein-1 interacts with NRIF3, an estrogen inducible nuclear receptor regulators. *Mol. Cell. Biol.* 24, 6581-6591, 2004.
103. Blasenthil, S., Barnes, C.J., Rayala, S.K., and Kumar, R. Estrogen receptor activation at Serine 305 is sufficient to upregulate Cyclin D1 in breast cancer cells. *FEBS Lett* 567, 243-247, 2004.
104. Mishra, S.K., Talukder, A., Gururaj, A., Yang, Z., Singh, R.K., Mahony, M., Franci, C., Vadlamudi, R.K., and Kumar, R. Upstream determinants of estrogen receptor regulation of MTA3 pathway. *J. Biol. Chem.* 279, 32709-32715, 2004.
105. Gururaj, A., Barnes. G.J., Vadlamudi, R.K., and Kumar, R. Phosphoglucomutase regulation by P21-activated kinases. *Oncogene* 23, 8118-8127, 2004.



106. Vadlamudi R.K., Balasenthil, S., Broaddus, R., Gustafsson, J.A, and Kumar, R. Deregulation of estrogen receptor coactivator PELP1/MNAR in human endometrial tumors. *J. Clin. Endo. Meta.* 89, 1-10, 2004.
107. Nair, S., Mishra, S. Yang, Z., Balasenthil, S., Kumar, R., and Vadlamudi, R.K. Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. *Cancer Research* 64: 6416-6423, 2004.
108. Qiao, M., Shapiro, P., Kumar, R., and Passaniti, A. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a PI3K/ERK-dependent and Akt-independent signaling pathway. *J Biol. Chem.* 279: 42709 - 42718, 2004.
109. Meng, G., Zhao, Y., Nag, A., Zeng, M., Dimri, G., Gao, Q., Wazer, D.E., Kumar, R., Band, H., and Band, V. Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation. *J. Biol. Chem.* 277, 45611-45618, 2004
110. Yang, Z., Vadlamudi, R.K., and Kumar, R. Dynein light chain 1 phosphorylation controls micropinocytosis, *J. Biol. Chem.* 280: 654- 659, 2005.
111. Yang, Z., Rayala, S., Nguyen, D., Vadlamudi, R., Chen, S, and Kumar, R. Pak1 phosphorylation of Snail, a Master Regulator of Epithelial-to-mesenchyme Transition, Modulates Snail's Subcellular Localization and Functions. *Cancer Research* 65, 3179-3184, 2005
112. Vadlamudi, R.K., Barnes, C., Rayala, S., Li, F., Marcus, S., Sahin, A. and Kumar, R. p21-activated kinase regulates microtubule biogenesis and dynamics via phosphorylation of Tubulin Cofactor B. *Mol. Cell. Biol.* 25, 3726-3736, 2005.
113. Barnes, C., Li, F. and Kumar, R. Growth factor regulation of a 26S proteasomal subunit in breast cancer. *Clinical Cancer Research*, 11, 2868-2874, 2005.
114. Vadlamudi, R.K., Manavathi , B., Singh, R.K., Li, F., Nguyen, D., and Kumar, R. An essential role of Pak1 phosphorylation of SHARP in Notch signaling. *Oncogene*, 24, 4591-4596, 2005.
115. Vadlamudi R.K., Balasenthil, S., Kies, M., Kumar, R and El-Naggar, A K. Expression of a Novel ER coactivator PELP1/MNAR and ER beta in salivary duct adenocarcinoma. *J. Human Pathology*, 36, 670-675, 2005.
116. Singh, R.K., Song, C., Yang, Z., and Kumar, R. Nuclear localization and chromatin targets of p21-activated kinase, *J. Biol. Chem.* 280, 18130 - 18137, 2005.
117. Bramanandam Manavathi, B, Nair, S., Wang, R, Kumar, R., and Vadlamudi,R.K. PELP1 is essential in growth factor regulation of STAT3 activation. *Cancer Research*, 65, 5571-5577, 2005.
118. Vadlamudi, R.K., Manavathi, B., Balasenthil, S., Yang, Z., Sahin, A. A., and Kumar, R. Functional implications of altered subcellular localization of PELP1 in cancer cells. *Cancer Research*, 65, 7724 - 7732, 2005.
119. Rayala, S.K., Hollander, P, Balasenthil, S., Yang, Z., Broaddus, R.R., and Kumar, R. Function regulation of estrogen receptor pathway by dynein light chain 1. *EMBO Report* 6, 538-545, 2005.

120. Singh, R.K., Barnes, C.J., Talukder, A.H., Fuqua, S.A.W. and Kumar, R. LIM only protein LMO4 represses estrogen receptor transactivation via MTA1 corepressor complex. *Cancer Research*, 65, 10594-10601, 2005.
121. Wang, RA, Zhao, M., Meistrich, M., and Kumar, R. Stage-specific Expression of Dynein Light Chain-1 and Its Interacting Kinase, p21-activated Kinase-1, in Rodent Testes: Implications in Spermitogenesis. *Journal of Histochemistry and Cytochemistry*, 53, 1235-12343, 2005.
122. Talukder, A.H., Meng, Q-C., and Kumar, R. CRIPak, a novel inhibitor of Pak1. *Oncogene* 25, 1311-1319. 2006.
123. Bagheri-Yarmand, R., Mazumdar, A., and Kumar, R. LIM-Kinase1 Increases tumor angiogenesis and invasiveness of breast cancer cells via regulation of urokinase-type plasminogen activator system. *International Journal of Cancer*, 118, 2703-1710, 2006.
124. Wang, R., Zhang, H., Balasenthil, S., Medina,D. and Kumar, R. PAK1 hyperactivation is sufficient for mammary gland tumor formation. *Oncogene* 25, 2931-2936, 2006.
125. Rayala, S.K., Balasenthil, S., andKumar, R. PAK1 regulation of estrogen receptor-alpha activation involves Serine 305 activation linked Serine 118 phosphorylation. *Cancer Research* 66, 1694-1701, 2006.
126. Rayala, S., Mascarenhas, J., Vadlamudi, R.K., and Kumar, R. Altered localization of a co-activator sensitizes breast cancer cells to TNF-induced apoptosis. *Mol. Cancer Therapeutics*, 5, 230-137, 2006.
127. Rayala SK, den Hollander P, Balasenthil S, Molli PR, Bean AJ, Vadlamudi RK, Wang RA, Kumar R. Hepatocyte growth factor regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK. *J Biological Chemistry*, 281, 4395-4403, 2006.
128. Holm, C, Rayala, S., Jirström, K., Stål O., Kumar, R., and Göran Landberg. Association of high Pak1 expression and nuclear localization with lack of tamoxifen response. *J. National Cancer Institute*, 98, 671 – 680, 2006.
129. Zhang, H., Clifton, S., and Kumar, R. MTA family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. *Clinical Cancer Research* 12, 1479-1486, 2006.
130. Filippo, A, Barnes, C.J., and Kumar, R. Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells, *Endocrinology*, 147, 1203-1212, 2006.
131. Qiao, M., Shapiro, P., Fosbrink, M., Rus, H., Kumar, R., and Passaniti, T. Cell cycle-restricted phosphorylation of RUNX2 by cdc2/cyclinB1 regulates endothelial cell proliferation. *Journal of Biological Chemistry* 281, 7118-7128, 2006.
132. Balasenthil, S., Broaddus, R, and Kumar, R. Expression of metastasis associated protein-1 (MTA1) in benign and endometrial adenocarcinomas. *Human Pathology* 37, 656-661, 2006.

133. Gururaj, A., Singh, R., Holmes, C., Rayala, S., denHollander, P., Talukder, A.H., Yang, Z., Hao, G., Balasenthil, S., Landberg, G., and Kumar, R. MTA1 targets breast cancer amplified sequence via a novel coactivator function. *Proc. Nat. Acad. Sci. USA*, 103, 6670-6675, 2006.
134. Wang, Y.-S., Ito, T., Wang, Y-H., Homey, B., Watanabe, N., Martin, R., Barnes, C.J., Gillet, M., Kumar, R., Yao, Z., and Liu, Y-J. Maintenance and progression of human T helper type 2 central memory T cells by thymic stromal lymphopoietin activated dendritic cells. *Immunity* 24, 827-838, 2006.
135. Singh RR, Gururaj AE, Vadlamudi RK, Kumar R. 9-cis-retinoic acid upregulates expression of transcriptional coregulator PELP1, a novel coactivator of RXR alpha pathway. *Journal of Biological Chemistry*, 281, 15394-15404, 2006.
136. DenHollander, P., and Kumar, R. DLC1 contributes to cell cycle progression by increasing CDK2 activity in breast cancer cells. *Cancer Research* 66, 5941-5949, 2006.
137. Cui, Y., Niu, A., Pestell, R., Kumar, R., Curran E.M., Fuqua, S.A.W. Metastasis-associated protein 2 is a repressor of estrogen receptor  $\alpha$  whose overexpression leads to estrogen-independent growth of human breast cancer cells. *Molecular Endocrinology*, 20, 2020-2035, 2006.
138. Rayala, S.K., den Hollander, P., Manavathi, B., Talukder, A.H., Song, C., Peng, S., Barnekow, A., Kremerskothen, J., and Kumar, R. Essential role of KIBRA in co-activator function of dynein light chain 1 in mammalian cells. *Journal of Biological Chemistry* 281, 19092-19099, 2006.
139. Gururaj, A., Holmes, C., Landberg, G., and Kumar, R. Breast Cancer–Amplified Sequence 3, a target of MTA1, contributes to tamoxifen resistance in premenopausal patients with breast cancer, *Cell Cycle*, 5, 1407-1410, 2006.
140. Mann, A.P., Verma, A., Sethi, G., Manavathi, B., Wang, H., Fok, J.Y., Kunnumakkara, A.Y., Kumar, R., Aggarwal, B.B., and Mehta, K. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor- $\kappa$ B in cancer cells: delineation of a novel pathway, *Cancer Research*, 66, 8788-8795, 2006.
141. Verma, A., Wang, H., Manavathi, B., Fok, J.Y., Mann, A.P., Kumar, R. and Mehta, K. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis, *Cancer Research* 66, 10525-10533, 2006.
142. Singh, R.R., Kaluarachchi, K.K., Rayala, S.K., Ma, J., Balasenthil, B., Chen, M., and Kumar, R. Solution structure and antiestrogenic activity of the unique C-terminal, NR-box motif-containing region of MTA1s. *Journal of Biological Chemistry*, 281, 25612 – 25621, 2006.
143. DenHollander, P., Rayala, S., Coverley, D. and Kumar, R. Ciz1, a novel DNA-binding coactivator of the estrogen receptor alpha, confers hypersensitivity to estrogen action. *Cancer Research*, 66, 11021-11029, 2006.
144. Filippo, A, Manavathi, B., Mascarenhas, J., Talukder, A., and Kumar, R. Integrin-linked kinase regulation of estrogen receptor- $\alpha$  activation. *Cancer Research*, 66, 11038 – 11046, 2006.

145. Ohshiro K, Rayala, S., Williams DM, Kumar R\*, and El-Naggar AK. Biological role of estrogen receptor-alpha in salivary gland adenocarcinoma cells. *Clinical Cancer Research*, 12, 5994 – 5999, 2006.
146. Bramanandan Manavathi, B., Acconcia, F., Rayala, S.K., and Kumar, R. An inherent role of microtubule network in the action of nuclear receptor. *Proc. Nat. Acad. Sci. USA*, 103, 15981 – 15986, 2006.
147. Zhang, H., Singh, R.K., Talukder, A.H., and Kumar, R. Metastatic tumor antigen 3 is a direct corepressor of WNT4 pathway. *Genes & Development*, 20, 2943 – 2948, 2006.
148. Nair SS, Guo Z, Mueller JM, Koochekpour S, Qiu Y, Tekmal RR, Schule R, Kung HJ, Kumar R, Vadlamudi RK. PELP1/MNAR enhances androgen receptor functions through LIM-only coactivator FHL2. *Molecular Endocrinology* 21, 613-624, 2007.
149. Meng, Q., Rayala, S., Gururaj, A.E., Talukder, A.H., O'Malley, B.W., and Kumar, R. Signaling-dependent and coordinated regulation of transcription, splicing, and translation resides in a single coregulator, PCBP1. *Proce. Nat. Acad. Sci. USA* 104, 5866-5871, 2007.
150. Acconcia, F., Barnes, C.J., Singh, R.R., Talukder, A.H., and Kumar, R. Phosphorylation-dependent regulation of nuclear localization and functions of integrin-linked kinase. *Proc. Nat. Acad. Sci. USA* 104, 6782-6787, 2007.
151. Barnes, CJ, Ohshiro, K., Rayala, SK, El-Naggar, AK, and Kumar, R. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. *Clinical Cancer Research*, 13, 4291-4299, 2007.
152. Ohshiro, K., Rayala, SK, Kondo, S., Guar, A., Vadlamudi, RK, El-Naggar, AK, and Kumar, R. Identifying the estrogen receptor coactivator PELP1 in autophagosomes. *Cancer Research*, 67, 8164-8171, 2007.
153. Yarmand, R., Balasenthil, S., Gururaj, A., Talukder, A.H., Lee, N., and Kumar, R. Metastasis associated protein-1 (MTA1) transgenic mice: a new model of spontaneous B-cell lymphomas. *Cancer Research*, 67, 7132-7138, 2007.
154. Balasenthil, S., Gururaj, A., Talukder, A.H., Yarmand, R., Lee, N., and Kumar, R. Identification of Pax5, as a target of MTA1 in B-cell Lymphomas. *Cancer Research*, 67, 7062-7067, 2007.
155. Manavathi, B., Rayala, S.K., and Kumar, R. Phosphorylation-dependent regulation of stability and transforming potential of ETS transcriptional factor ESE-1 by p21-activated kinase 1. *Journal of Biological Chemistry* 282, 19820-19830, 2007.
156. Rajhans, R., Nair, S., Holden, A.H., Kumar, R., Tekmal, R.R., and Vadlamudi R.K. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. *Cancer Research* 67, 5505-5512, 2007.
157. Manavathi, B., Peng, S., Rayala, S.K., Talukder, A.J., Wang, M., Wang, R., Balasenthil, S., Agarwal, N., Frishman, L.J., and Kumar, R. Repression of Six3 by a Corepressor Regulates Rhodopsin Expression. *Proc. Nat. Acad. Sci. USA* 104, 13128-13133. 2007.

158. Aoki, H., Yokoyama, T., Fujiwara, K., Tari, A., Sawaya, R., Suki, D., Hess, R., Aldape, KD, Kondo, S., Kumar, R., Kondo, Y. Phosphorylated Pak1 Level in the cytoplasm correlates with a shorter survival time in patients with glioblastoma. *Clinical Cancer Research*, 13, 6603-6609, 2007.
159. Fontenot, D., Hollander; P., Vela, E.M., Newman, R., Sastry, J., Kumar, R. Dynein Light Chain 1 Peptide Inhibits Human Immunodeficiency Virus Infection in Cells. *Biochem Biophys Res Comm.* 363, 901-907, 2007.
160. Rayala, S.K., Martin, E., Sharina, I.J., Molli, P., Wang, X., Wang, R., Jacobson, R., Murad, F., and Kumar, R. Coordinated regulation of nitration and phosphorylation of tubulin cofactor B in microtubule dynamics. *Proc. Nat. Acad. Sci. USA* 104, 19470-19475, 2007.
161. Song, C., Wen, W., Rayala, S.K., Chen, M., Ma, J., Talukder, A.H., Zhang, M., and Kumar, R. Serine 88 phosphorylation of the 8 kDa dynein light chain is a molecular switch for its dimerization status and functions. *Journal of Biological Chemistry*, 283, 4004-4013, 2008.
162. Molli, P.R., Singh, R.R., Lee, S.W., and Kumar, R. MTA1-mediated repression of BRCA1 tumor suppressor gene. *Oncogene*, 27, 1971-1980, 2008.
163. Talukder, A., Li, D.Q., Manavathi, B, and Kumar, R. Serine 28 phosphorylation of NRIF3 confers its coactivator function for estrogen receptor-alpha transactivation. *Oncogene*, 27, 5233-5242, 2008.
164. Akinmade, D., Talukder, A., Kumar, R., and Hamburger, A.W. Phosphorylation of the ErbB3-binding protein Ebp1 by p21-activated kinase1 (PAK1) in breast cancer cells. *British J Cancer*, 98:1132-1140, 2008.
165. Naresh, A., Marrero, L., Kumar, R., and Jones, F.E The HER4/4ICD BH3-Only Protein is an effector of tamoxifen-induced apoptosis. *Cancer Research*, 68, 6387-6395, 2008.
166. Molli, P., Adam, L., and Kumar, R. Therapeutic IMC-C225 antibody mediated inhibition of cancer cell migration involves activation of RhoA GTPase via Vav2. *Clinical Cancer Research*, 14:6161-6170, 2008.
167. Reddy, S.D.N., Ohshiro, K., Rayala, S., and Kumar, R. MicroRNA-7, a homeobox D10 target, inhibits the p21-activated kinase 1 and regulates its functions. *Cancer Research*, 68:8195-8200, 2008.
168. Tharakan, R., Lepont, P., Singleton, D., Kumar, R., and Khan, S. Phosphorylation of estrogen receptor alpha, serine residue 305 enhances activity. *Mol Cell Endocrinol.* 295:70-78, 2008.
169. Reddy, S.D.N., Pakala, S.B., Ohshiro, K., Rayala, S., and Kumar, R. MicroRNA-661, a c/EBP $\alpha$  target, inhibits the metastatic tumor antigen 1 and regulates its functions. *Cancer Research* 69: 5639-5642, 2009.
170. Kumar, R., Zhang, H, Holm, C, Pakala, SK, Vadlamudi, RK, Landberg, G., and Rayala, S. Extranuclear coactivator signaling confers insensitivity to tamoxifen. *Clinical Cancer Research* 15: 4123-4130, 2009.
171. Popov, V., Zhou, J., Shirley, DA, Quong, J., Yeow, W., Wright, J., Wu, K., Rui, H., Vadlamudi, R., Jiang, J., Kumar, R., Wang, C., and Pestell, R. The Cell Fate Determination Factor DACH1 is

- expressed in Estrogen Receptor  $\alpha$  (ER $\alpha$ ) positive breast cancer and represses ER $\alpha$  signaling. *Cancer Research* 69:5752-5760, 2009.
172. Li, D-Q., Ohshiro, K., Reddy, SDN, Pakala, S.B., Lee, M-H., Zhang, Y., Rayala, S.K., and Kumar, R. E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. *Proc. Nat. Acad. Sci. USA*. 106:17493-17498, 2009.
173. Li, D-Q., Reddy, S.D., Pakala, S.B., Wu, X., Zhang, Y., Rayala, S.K., Kumar, R. MTA1 coregulator regulates p53 stability and function. *J Biol Chem*, 284: 34545-34552, 2009.
174. Bui-Nguyen, T., Pakala, SB, Sirigiri, RD, Xia, Y, Hung, MC, Sarin, SK, Kumar, V., Slagle, BL, and Kumar, R. NF- $\kappa$ B signaling mediates the induction of MTA1 by Hepatitis B virus transactivator protein HBx. *Oncogene*, 29:1179-1189, 2010.
175. Long, W., Yi, P., Lamarca, HL, Ashcroft F, Kumar, R., Mancini, M.A., Tsai, S.Y., Tsai, M-J., O'Malley, B.W. SRC-3.DELTA4 mediates the interaction of EGFR with FAK to promote cell migration. *Molecular Cell* 37:321-332, 2010.
176. Li, D-Q., Pakala, S.B., Reddy, S.D., Ohshiro, K., Peng, Q., Fu, S., Kumar, R. Revelation of p53-independent function of MTA1 in DNA damage response via modulation of p21WAF1-PCNA. *J. Biol. Chem.* 285:10044-10052, 2010.
177. Ohshiro, K., Prikariti, V, Meng, Q, Rayala, SK, Sahin, A., Fuqua, SAW, Kumar, R. Identification of a novel estrogen receptor alpha variant and its upstream splicing regulator. *Molecular Endocrinology*, 24: 914 – 922, 2010
178. ChakravartyD, Nair SS, Santhamma B, Nair BC, Wang L, Bandyopadhyay A, AgyinJA, Brann D, Sun S, Yeh I, Lee FY, Tekmal R, Kumar R and Vadlamudi RK. Extranuclear functions of ER impact invasive migration and metastases of breast cancer cells. *Cancer Research*, 70: 4092-4101,2010.
179. Li, D-Q, Ohshiro, K., Khan M. N., and Kumar, R. Requirement of MTA1 in ATR-mediated DNA damage checkpoint function. *J. Biol Chem*, 285:19802-19812, 2010.
180. Molli, P., Li, D-Q., Bagheri-Yarmand, R., Katayama, H., Sen, S, Iyer, J., Chernoff, J., Tsai, M.Y., Nair, S. S. and Kumar, R. Apc1b, a new centrosomal protein, is both an activator and substrate of Aurora A. *Journal of Cell Biology*, 190, 101-114, 2010.
181. Kumar, R., Seetharaman, B., Pakala, S.B, Sahin, A, and Kazufumi, O. Metastasis associated protein 1 short-form stimulates Wnt1 pathway in mammary epithelial and cancer cells. *Cancer Research* 70:6590–6600, 2010.
182. Kumar, R., Balasenthil, B., Manavathi, B., Rayala, S., and Pakala, S.B. Metastasis associated protein 1 and its short form variant stimulates Wnt1 transcription via promoting its derepression from Six3 corepressor. *Cancer Research* 70:6649–6658, 2010.
183. Li, Y., Cao, H., Jiao, Z., Pakala, S.B., Sirigiri, D.N., Li, W., Kumar, R., and Mishra, L. Carcinoembryonic antigen interacts with TGF- $\beta$  receptor and inhibits TGF- $\beta$  signaling in colorectal cancers. *Cancer Research* 70:8159-8168, 2010.

184. Nair BC, Nair S, Chakravarty D, Manavathi B, Yew R, Kumar R, Tekmal R, and Vadlamudi R. CDK-mediated phosphorylation play a critical role in PELP1's oncogenic functions. *Cancer Research* 70:7166-7175, 2010.
185. Ohshiro, K., Rayala, S., Holm, C., Pakala, S.B., Devijendra, RS, Molli, P.R., Gururaj, A.E., Månsson, S.S., Ramezani, A., Hawley, R., Landberg, G., Lee, NH, and Kumar R. Acetylation-dependent Oncogenic Activity of MTA1 Coregulator. *EMBO Report* 11:691-697, 2010.
186. Yingjie Xu, Y., Bismar, T.A., Su, J., Xu, B., Kristiansen, G., Teng, G.Z.V., Ingber, D.E., Mammoto, A., Kumar, R., and Alaoui-Jamali, M.A. Filamin-A regulates focal adhesion disassembly to suppress cancer cell migration and invasion. *J. Exp. Med.* 207:2421-2437, 2010.
187. Pakala SB, Divijendra Natha Reddy S, Bui-Nguyen TM, Rangparia SS, Bommana A, Kumar R. MTA1 coregulator regulates LPS response via MyD88-dependent signaling. *J Biol Chem.* 285:32787-32792, 2010.
188. Yao, Z-X, Jogunoori, W.JR, Choufani, S., Rashid, A., Blake, T., Yao, W., Kreishman, P., Amin, R., Sidawy, AA, Evans, S.R.T., Finegold, M., Reddy, E.P., Mishra, B., Weksberg, R., Kumar, R., and Mishra, L. Epigenetic silencing of  $\beta$ -spectrin a TGF- $\beta$  signaling/scaffolding protein in a human cancer stem cell disorder: Beckwith-Wiedemann syndrome *J. Biol. Chem.* 285:36112-36120, 2010.
189. Ghanta, K.S., Pakala, S.B., Reddy, S.D., Li, D.Q., Nair, S.S., Kumar. R. MTA1 coregulation of transglutaminase 2 expression and function during inflammatory response. *J Biol Chem.* 286:7132-7138, 2010.
190. Ghanta, K.S., Li, D.Q., Esware, J, Kumar. R. Gene profiling of Mta1 identifies novel gene targets and functions. *PLoS One* – 6(2):e17135, 2011.
191. SB Pakala, S.B., Singh, K., Ohshiro, K, Li, D-Q., Mishra, L, and Kumar R. TGF-b1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells. *Oncogene* 30:2230-2241, 2011.
192. Reddy, S.D.N., Rayala, S., Ohshiro, S, Pakala, S,B., Kobori, N., Dash, NK, Yun, S., Qin, J., O'Malley, B.W., and Kumar, R. Multiple coregulatory control of tyrosine hydroxylase gene transcription. *Proc. Nat. Acad. Sci. USA* 108:4200-4205. 2011.
193. Li, DQ, Pakala, SB, Reddy, SDN, Ohshiro, K, Zhang, JX, Wang, L, Zhang, Y, Alborán, IMD, Pillai, MR, Eswaran, J, and Kumar, R. Bidirectional autoregulatory mechanism of metastasis-associated protein 1-alternative reading frame pathway in oncogenesis. *Proc. Nat. Acad. Sci. USA.*,108: 8791-8796 2011.
194. Cong L, Pakala SB, Ohshiro K, Li DQ, Kumar R. SUMOylation and SUMO-interacting motif of metastasis tumor antigen 1 synergistically regulate its transcriptional repressor function. *Journal of Biological Chemistry*, 286: 43793-43808. 2011.
195. Zhang JX, Li DQ, He AR, Motwani M, Eswaran J, Mishra L, Kumar R. Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly(ADP-ribose) polymerases. *Hepatology*, 55(6):1840-1851, 2011.
196. Ha NH, Nair VS, Reddy SDN, Mudvari P, Ohshiro K, Ghanta KS, Pakala SB, Li DQ, Costa L , Lipton A, Badwe RA, Fuqua SAW, Wallon M, Prendergast GC, Kumar R. Lactoferrin-endothelin-1

axis contributes to the development and invasiveness of triple negative breast cancer phenotypes. *Cancer Research*, 71:7259-7269, 2011.

197. Ohshiro K, Shwach, A, Levin, O., Kumar R. Alternate Estrogen Receptors Promote Invasion of Inflammatory Breast Cancer Cells via Non-genomic Signaling. *PLoS One*. *PLoS ONE* 7(1): e30725. doi:10.1371.
198. Eswaran, J., Cyanam, D., Mudvari, P., Reddy, S.D.N., Pakala, S.B., Nair, S.S., Florea, L., Fuqua, S.A., Godbole, S., and Kumar, R. Transcriptomic landscape of breast cancers through mRNA sequencing. *Sci Rep*. 2012;2:264.
199. Reddy, S.D.N., Pakala, S.B., Mlli, P.R., Sahna, N., Karanam, N.K, Mudvari, P., and Kumar, R. Metastasis associated protein 1/Histone Deacetylase 4-Nucleosome Remodeling and Deacetylase Complex Regulates PTEN Expression and Function. *J. Biol. Chem.* 287: 27843-27850, 2012.
200. Sánchez-Solana, B., Motwani, M., Li, D., Eswaran, J., and Kumar, R. P21-activated kinase-1 signaling regulates transcription of tissue factor and tissue factor pathway inhibitor. *J. Biol. Chem.* 287:39291-302, 2012.
201. Pakala, S.B., Nair, V.S., Reddy, S.D.N., and Kumar, R. Signaling-dependent phosphorylation of Mitotic Centromere Associated Kinesin regulates microtubule depolymerization and its centrosomal localization. *J. Biol. Chem.* 287:40560-569, 2012.
202. Li, D-Q, Nair, SS, Ohshiro, K., Kumar, A., Nair, VS, Pakala, SB, Reddy, SDN, Gajula, RP, Eswaran, J, Aravind L., and Kumar, R. MORC2 Signaling Facilitates Phosphorylation-dependent, ATPase-coupled Chromatin Remodeling during the DNA Damage Response. *Cell Report*, 2, 1657–1669, 2012.
203. Ohshiro K, Bui-Nguyen TM, Divijendra Natha RS, Schwartz AM, Levine P, Kumar R. Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway. *Int J Biol Markers*. doi: 10.5301/JBM.2012.10437. PMID: 23280128, 2012.
204. Nair SS, Li DQ, and Kumar R. Core Chromatin Remodeling Factor Instructs Global Chromatin Signaling through Multivalent Reading of Nucleosome Codes. *Molecular Cell* 49, 704-718, 2013.
205. Eswaran, J, Horvath A, Godbole S, Reddy, SD, Mudvari P, Ohshiro, K, Pakala SB, Cyanam D, Nair SS, Fuqua S, Polyak K, Florea L, and Kumar R. RNA sequencing of cancer reveals novel splicing alterations. *Scientific Reports* 3: 1689. 2013.
206. Pakala, SB, Rayala, SK, Wang, AA, Ohshiro, K, Mudvari, P, Reddy, SDN, Sirigiri Divijendra, Zheng, Y, Pires, R, Casimiro, S, Pillai, SR, Costa, L, and Kumar, R. MTA1 Promotes STAT3 Transcription and Pulmonary Metastasis in Breast Cancer. *Cancer Research*, 73:3761-3770, 2013.
207. Motwani, M, Li, DQ, Horvath A, and Kumar, R. Identification of novel gene targets and functions of p21-activated kinase 1 during DNA damage by gene expression profiling. *PLOS-One* (8):e66585, 2013.
208. Horvath A, Pakala, SB, Mudvari P, Reddy, SD, Ohshiro, Casimiro, S, Pires, R, Fuqua, SWA, Costa, L, Toi, M, Nair, SS, Sukumar, S, and Kumar, R. Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing. *Scientific Reports* 3: 2256, 2013.



209. Feng, Y, Singleton, D, Guo, C, Gardner, A, Pakala, S, Kumar, R, Jensen, E, Zhang, J, and Khan, S. DNA homologous recombination factor SFR1 physically and functionally interacts with ER-alpha. *PLoS ONE* 8(7): e68075, 2013.
210. Li, D.Q., Pakala, S.B., Reddy, S.D., Peng, S., Balasenthil, S., Lee, C.C., Rea, M.A., and Kumar, R. MTA1 is an integral component of the circadian molecular machinery. *Nature Communication* 4:2545. doi: 10.1038/ncomms3545, 2013.
211. Mudvari, P., Ohshiro, K, Nair, V., Horvath, A, and Kumar, R. Genomic insights into Triple-negative and HER2-positive breast cancers using isogenic model systems. *PLOS One* 8(9):e74993,2013.
212. Covington, KR, Brusco, L., Barone, I, Tsimelzon, A., Selever, J., Corona-Rodriguez, A., Brown, P., Kumar, R., Hilsenbeck, S.G., and Suzanne A. W. Metastasis Tumor Associated Protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. *Breast Cancer research and Treatment*, 141 (3), pp 375-384, 2013.
213. Sánchez-Solana, B., Li, D.Q, and Kumar, R. Cytosolic functions of MORC2 in lipogenesis and adipogenesis. *BBA-Mole. Cell Research* 1843(2):316-26, 2014.
214. Bao, W, Florea, L., Wu, N., Wang, Z., Banaudha, K., Qian, J. Houzet, L., Kumar, R., and Kumar, A. Loss of nuclear PTEN in HCV-infected human hepatocytes. *Infectious Agents and Cancer* 9:23, 2014 doi:10.1186-9-
215. Ohshiro, K., and Kumar, R. MTA1 regulation of ER-beta pathway in salivary gland carcinoma cells. *Biochem Biophys Res Commun.* 464, 1016-1021, 2015.
216. Luo, L., McGarvey, P., Madhavan, S., Kumar, R., Gusev, Y., Upadhyay, G. Distinct Lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis. *Oncotarget*, 7(10):11165-11193, 2016
217. Hossiny, MA, Luo, L., Frazier, W., Steiner, N., Gusev, Y., Glasgow, E., Creswell, K., Kumar, R., and Upadhyay, G. Lymphocyte antigens 6 complex K/E-transforming growth factor-beta axis promotes breast cancer tumorigenesis, drug resistance and tumor immune escape. *Cancer Research* 76, 3376-3386, 2016.
218. Parvathy, M., Sreeja, S., Kumar, R., and Pillai, M.R. Potential role of p21 activated kinase (PAK1) in the invasion and motility of cancer cells. *BMC Cancer*, 16 (suppl.1), 2016. <http://dx.doi.org/10.1186/s12885-016-2263-8>
219. Bliss, S.A., Sinha, G, Sandiford, O.A., Williams, L., Engelberth, D.J., Guiro, K., Isenalumhe, L.L., Greco, S.J., Bryan, M., Kumar, R., Ponzio, N, and Rameshwar, P. Mesenchymal Stem Cell-derived Exosomes with MicroRNA Stimulates Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow. *Cancer Research* 76:5832-5844, 2016.
220. Dong, H., Ma, L., Lin, W., Gan, J., Chen, C., Yao, Z., Du, L., Zheng, L., Ke, C., Huang, X., Song, S., Kumar, R, Yung, SC, Zhang, H. PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endocytotic degradation of ERBB2. *Oncogene* 36:410-422, 2017.

221. Marzook, H., Deivendran, S., Kumar, T.R.S., Kumar\*, R., and Pillai\*, M.R. Cytoplasmic translocation of MTA1 coregulator promotes de-repression of *SGK1* transcription in hypoxic cancer cells. *Oncogene* 36:5263-5273, 2017.
222. Deivendran, S., Marzook, H., Santhosh Kumar, T.R., Kumar\*, R., Pillai\*, M. R. MTA1, a novel regulator of DNMT3a, stimulates insulin-growth factor binding protein-3 in human cancer. *Scientific Report* 7, 44225, 2017.
223. Qin, JH, Ke, ZY, Zhou, Q, Wang, L, Wang, YM, Yang, T, Gao, X, Ye, Y, Kumar, R, Wang, R. Metastasis-associated protein 1 regulates pulmonary alveolar capillary angiogenesis in mouse. *Med Sci Monit.* 23:3932-3941, 2017.
224. Ganju, A., Chauhan, S.C., Hafeez, B.B., Tripathi, M.K., Zafar, N., Yallapu, M.M., Kumar, R., Jaggi, M. Protein kinase D1 regulates subcellular localization and metastatic function of metastatic associated protein 1. *British J. Cancer* 118:587-599, 2018.
225. Li, Y., Zhang, H., Zhao, H., Zhao, Y., Wang, C., Cheng, Z., Tang, L., Gao, Y., Liu, F., Li, J., Li, Y., Li, Y., Geng, N., Rui, X, Teng, Y., Liu, Y., Cao, L., Kumar, R., Jin, F., Li, F. Nuclear PAK4 as a novel potential target for ER $\alpha$ -positive breast 1 cancer bone metastasis. *Oncogene – In Press*.

## REVIEW ARTICLES

226. Kumar R and Vadlamudi R. EGF family of growth factors. *J. Cli. Ligand Assay* 3, 233-238, 2000.
227. Kumar R, Vadlamudi R, and Adam L. Mammary gland development and cancer. *Endocrine Related Cancer*7, 271-284, 2000.
228. Kumar R and Yarmand RB. HER2 signaling in angiogenesis. *Seminars in Oncology* 28, 27-32, 2001.
229. Kumar, R. Targeting epidermal growth factor receptor family members for treatmentof breast cancer. *Biological Therapy of Breast Cancer* 3, 3-6, 2001.
230. Kumar, R. and Wang, R. Protein kinases in mammary gland development andcancer. *Microscopy Research and Technique*59, 49-57, 2002.
231. Kumar, R. and Vadlamudi, R. Emerging functions of p21-activated kinases inhuman cancer cells. *J. Cell. Physiol.* 193, 133-144, 2002.
232. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, and Yue W. The role of MAP kinase in breast cancer. *J. Steroid Bioch. & Mol. Biol* 80, 239-256, 2002.
233. Kumar, R., Wang, R.W., and Bagheri-Yarmand, R. Emerging roles of MTA familymembers in human cancers. *Semin Oncol*5, 30-37, 2003.
234. Barnes, C.J., and Kumar, R. Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets. *Cancer & Metastasis Reviews* 22, 301-307, 2003.
235. Vadlamudi, R., and Kumar, R. Evolving significance of p21-activated kinases inhuman cancer. *Cancer & Metastasis Reviews*, 22, 385-393, 2003.

236. Santen, RJ, Song, RX, Zhang, Z, Kumar, R, Jeng, MH, Masamura, S, Yue, W, and Berstein, L. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over SERMS for breast cancer treatment and prevention. *Endocrine-Related Cancer*, 10, 111-130, 2003.
237. Kumar, R. Another Tie that binds MTA family to breast cancer. *Cell* 113, 142-143, 2003.
238. Barnes, C.J., Vadlamudi, R.K., and Kumar, R. Novel estrogen receptor coregulators in human diseases. *Cellular and Molecular Life Sciences* 61, 281-291, 2004.
239. Santen, R.J. Song, R.X., Zhang, Z., Yue, W. and Kumar, R. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. *Clin Cancer Res.* 10, 337S-345S, 2004.
240. Kumar, R., Wang, Rui-An, Barnes, C.J. Coregulators and chromatin remodeling in transcriptional control. *Mol Carcinogenesis*, 41, 221-230, 2004.
241. Gururaj, A.E., Rayala, S.K., and Kumar, R. PAK signaling in breast cancer. *Breast Cancer Research*, 8, 5-12, 2005.
242. Kumar, R. and Hung, M-H., Signaling intricacies take a center stage in cancer cells. *Cancer Research* 65, 2511-2515, 2005.
243. Kumar, R, Gururaj, A., Vadlamudi, R., and Rayala, S. Clinical significance of steroidal receptor corepressors. *Clinical Cancer Research*, 11, 2822 - 2831, 2005.
244. Singh, R., and Kumar, R. Steroid hormone receptor signaling in tumorigenesis. *J. Cellular Biochemistry* 96, 490-505, 2005.
245. Acconcia, F., and Kumar, R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. *Cancer Lett*, 238, 1-14, 2005.
246. Santen, R.J., Song, R.X., Zhang, Z., Kumar, R., Jeng, M-H., Masamura, S., Lawrence, J. Jr., Berstein, L., Yue, W. Long term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. *Endocrine-Related Cancer*, Suppl 1, S61-73. 2005.
247. Kumar, R. Commentary: Targeting colorectal cancer through molecular biology. *Seminars in Oncology*, 32 (6 Suppl 9), S37-39, 2005.
248. Gururaj, A.E., Rayala, S.K., Vadlamudi, R.K., and Kumar, R. Novel mechanisms of resistance to endocrine therapy – genomic and nongenomic considerations. *Clinical Cancer Research* 12, 1001s-1007s (Suppl), 2006.
249. Manavathi, B., and Kumar, R. Steering estrogen signals from the plasma membrane to the nucleus: a tale of two sides of coin. *J. Cellular Physiology*, 207, 59-604, 2006.
250. Filippo Acconcia, F. and Kumar, R. Loss of PAX-2 methylation: The turning point of endometrial cells to the dark side of proliferation. *Cellsciences Review* 2 (3), ISSN 1742.8130, Online 2006.

251. Rayala, S., Molli, P., and Kumar, R. Nuclear PAK1 in breast cancer packs off tamoxifen sensitivity. *Cancer Research*, 66:5985-5988, 2006.
252. Kumar, R. A look backward to move forward. Scientists in reflections. *Cancer Biology & Therapy* 5, 554-556, 2006.
253. Kumar, R., Gururaj, A., and Barnes, C.J. p21-activating kinases in cancer. *Nature Review Cancer* 6, 459- 462, 2006.
254. Manavathi, B. and Kumar, R. Metastasis tumor antigens antigens, an emerging family of multifaceted master coregulators. *Journal of Biological Chemistry*, 282, 1529-1533, 2007.
255. Singh, R.R., and Kumar, R. MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer. *Journal of Mammary Gland Biology and Neoplasia*, 12: 115-125, 2007.
256. Rayala, S. and Kumar, R. Sliding p21-activated kinase 1 to the nucleus impacts tamoxifen sensitivity. *Biomedicine and Pharmacotherapy*, 61:408-411, 2007.
257. Vadlamudi RK, and Kumar R. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. *Nuclear Receptor Signal*. 2007 May 17;5:e004.
258. Kumar, R. ErbB-dependent signaling as a determinant of trastuzumab resistance. Commentary – *Clinical Cancer Research*, 13, 4657-4659, 2007.
259. Manavathi, B., Singh, K. and Kumar, R. MTA1 family of coregulators in nuclear receptor signaling. *Nuclear Receptor Signal*, e010, 2007.
260. Ohshiro, K., Rayala, SK, El-Naggar, AK, and Kumar, R. Delivery of cytoplasmic proteins to autophagosomes. *Autophagy* 4, 104-106, 2008.
261. Klionsky, D. et al (+218 coauthors). Guidelines for the Use and Interpretation of assays for monitoring autophagy in higher eukaryotes. *Autophagy*, 4, 141-150, 2008.
262. Eswaran, J., Soundararajan, M., Kumar, R., Knapp, S. UnPAKing the class differences in p21 activated kinase family. *Trends in Biochemical Sciences (TIBS)*, 33, 394-403, 2008.
263. Molli, P., Li, D-Q, Murray, B.W., Rayala, S.K. and Kumar, R. PAK Signaling in Oncogenesis. *Oncogene* 28:2545-2555, 2009
264. Kumar, A., Molli, P.R., Pakala, S.B., Bui Nguyen, T.M., Rayala, S.K, and Kumar, R. PAK thread from amoeba to mammals. *Journal of Cellular Biochemistry* 107: 579-585, 2009.
265. Ohshiro, K., and Kumar, R. Evolving Pathway-driven Biomarkers in Breast Cancer – *Expert Opin Investig Drugs*. 9 Suppl 1:S51-6, 2009.
266. O'Malley, B.W., and Kumar, R. Nuclear receptor coregulators in cancer biology. *Cancer Research* 69:8217–8222, 2009.

267. Kumar R, and Hall A. Actin and microtubule cytoskeletons in the development and maintenance of cancer phenotypes. Preface. *Cancer Metastasis Rev.* 28(1-2):3, 2009.
268. Dummler B, Ohshiro K, Kumar R, and Field J. Pak protein kinases and their role in cancer. *Cancer Metastasis Rev.* 28(1-2):51-63, 2009.
269. Lonard, D., Kumar, R. and O'Malley, B.W. The SRC Family of Coactivators: An Entree To Understanding A Subset of Polygenic Diseases? *Molecular Endocrinology* 24:279-285, 2010.
270. Reddy, S.D., Gujula, R., Pakala, S.B., and Kumar, R. MicroRNAs and Cancer Therapeutics: The next wave or here to stay. *Cancer Biology & Therapy*, 4: 9(7), 479 – 482, 2010.
271. Zhang JX, Li DQ, Kumar R. P21-activated kinase 1 and breast cancer. *Chinese Journal of Breast Disease*, 2010; 4: 544-553, 2010.
272. Li DQ, Kumar, R. Mi-2/NuRD Complex Making Inroads into DNA-damage Response Pathway. *Cell Cycle*, 9 (11), 2071-2079, 2010.
273. Li DQ, Pakala SB, Nair SS, Eswaran J, Kumar R. Metastasis associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer. *Cancer Research*, 72:387-394, 2012.
274. Eswaran J, Li DQ, Shaw A, Kumar R. Molecular Pathways: Targeting P21-activated Kinase 1 Signaling in Cancer: Opportunities, Challenges and Limitations. *Clinical Cancer Research* 18:3743-3749, 2012.
275. Li DQ, and Kumar R. Targeting chromatin remodelers to treat hepatocellular carcinoma-Reply. *Hepatology*. 2012 Jul 19. PMID: 22815144
276. The Global Cancer Genomics Consortium. The Global Cancer Genomics Consortium: Interfacing Genomics and Cancer Medicine. *Cancer Research*, 72(15):3720-3724, 2012.
277. Manavathi B, Dey O, Reddy VN, Bhatia RS, Bugide S, and Kumar R. Derailed Estrogen Signaling and Breast Cancer: an Authentic Couple. *Endocrinology Review*, 34, 1-34, 2013.
278. Nair, S, and Kumar, R. Chromatin Remodeling in Cancer: A Gateway To Regulate Gene Transcription. *Molecular Oncology* 6(6):611-9, 2012.
279. Kumar, R, Horvath, A., Mazumder, R., Toi, M., Sato, F., Pillai, RM, Costa, L., Carmo-Fonseca, M., Knapp, S., Dutt, A., Gupta, S., and Badwe, R. Global Cancer Genomics Consortium. The Global Cancer Genomics Consortium Second Annual Symposium: Genomics Medicine in Cancer Research. *Genes and Cancer*, 4: 196-200, 2013.
280. Li, DQ, Nair, S.S., and Kumar, R. The MORC Family: New Epigenetic Regulators of Transcription and DNA Damage Response. *Epigenetics* 8(7), 685-93, 2013.
281. Costa, L. Casimiro, S., Knapp, S., Pillai, MR, Gupta, S., Badwe, R., Toi, M., Carmo-Fonseca, M., Kumar, R. The Global Cancer Genomics Consortium's Third Annual Symposium: From Oncogenomics to Cancer Care. *Genes & Cancer*, 5 (3-4), 64-70, 2014.

282. Sen, N., Gui, B, and Kumar, R. Physiological functions of MTA family of proteins. *Cancer Metastasis Rev.* 33 (4), 869-877, 2014.
283. Sen, N., Gui, B, and Kumar, R. Role of MTA1 in Cancer Progression and Metastasis. *Cancer Metastasis Rev.* 33(4), 891-900, 2014.
284. Marzook,H., Deivendran S, Kumar, R. and M.R. Pillai. Role of MTA1 in head and neck cancers. *Cancer Metastasis Rev.* 33(4), 953-964, 2014.
285. Li, D-Q., Yang, Y., and Kumar, R. MTA family of proteins in DNA damage response: mechanistic insights and potential applications. *Cancer Metastasis Rev.* 33(4) 993-1000, 2014.
286. Toi, M., Pillai, RM, Gupta, S., Badwe, R., Carmo-Fonseca, M., Costa, L., Chow, LWC, Knapp, S., and Kumar, R. The Global Cancer Genomics Consortium's Symposium: New Era of Molecular Medicine and Epigenetic Cancer Medicine - Cross Section of Genomics and Epigenetics. *Genes & Cancer* 6(1-2), 1-8, 2015.
287. Li, Da-Qing and Kumar, R. Unravelling the Complexity and Functions of MTA Coregulators in Human Cancer. *Adv. in Cancer Research, Volume 127, 1-47, 2015.*
288. Chow, L, Costa, L., Teh, BT, Li, DQ, Guan, XY, Nair, A., Li, Z., Sugimoto, M, and Kumar, R. Cancer Genomics and Biology 2015. *Genes and Cancer, On-line DOI: 10.18632/genesandcancer.92, 2016.*
289. Kumar, R. Observations on Radiation-Induced Lymphoid Tumors of Mice. *Cancer Research* 76:511-512, 2016.
290. Kumar, R., Da-Qing, Muller, S., and Knapp, S. Epigenomic Regulation of Oncogenesis by Chromatin Remodeling. *Oncogene* 35, 4423-4436, August 2016.
291. Kumar, R. and Li, Da-Qing. PAKs in Human Cancer Progression – From Inception to Therapeutic Target to Future Oncobiology. *Advances in Cancer Research, 130, 137-209, 2016.*
292. Kumar, R., Wang, R-W. Structure, Expression and Functions of MTA Genes, *GENE*582:112-121, 2016.
293. Kumar, R., Reflecting Back to Bring Nitric Oxide Research to the Laboratory, *Current Medical Chemistry* 23, 2637-2642, 2016.
294. Kumar, R., Sanawar, R., Li, X., and Li, F. Structure, Expression and Functions of PAK Genes, *GENE* 605:20-31, 2017.
295. Kumar, R., Deivendran, S., Santhosh Kumar, T.R., Pillai, MR. Signaling Coupled Epigenomic Regulation of Gene Expression. *Oncogene*36:5917-5926, 2017.

## BOOKS/VOLUMES

1. Molecular Signaling and Therapeutics  
Editor: R Kumar  
Kluwer Press, 2004; Pages 327; ISBN: 1-4020-7822-6
2. NR Coregulators and Human Diseases  
Editors: Rakesh Kumar & Bert W. O'Malley  
World Scientific Publishers 2008; Pages 602; ISBN: 10-9812705368
3. Nuclear Signaling Pathways and Targeting Transcription in Cancer  
Editor: R. Kumar  
Springer Press 2013; Pages 441 (16 chapters); ISBN 978-1-4614-8038-9
4. Protein Kinases in Cancer  
Editor - Rakesh Kumar  
Cancer Metastasis Reviews 22, Number 4, pp297-472 (15 articles), 2003.  
ISSN: 0167-7659 (Print)
5. Cytoskeleton Signaling in Cancer.  
Editors - Rakesh Kumar and Alan Hall  
Metastasis Cancer Reviews 28 (1-2), pp1-263 (23 articles), June 2009. ISSN: 0167-7659 (Print)
6. Functions and Clinical Relevance of MTA Proteins in Human Cancer  
Editor - Rakesh Kumar  
Cancer Metastasis Reviews 33 (4), pp837-1127 (27 articles), Dec 2014. ISSN: 0167-7659 (Print)